← Leaderboards
Thomas D Y Chung
Colorado State University
$4,119,569
Attributed
$9,103,010
Total exposure
6
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2M · FY2019–25$2M$1.5M$1M$500K$0
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$9,103,010 · 6
By mechanism
R01$5,617,810 · 4
R33$2,631,315 · 1
R61$853,885 · 1
Top collaborators
- James K Chen5 shared
- Chaoping Chen4 shared
- Yonghe Li4 shared
- David H Sherman4 shared
- Oliver Bell1 shared
- Wendong Huang1 shared
Most similar at Colorado State University
Same institution · by research overlap
- B. George Barisas$820,130
Others in their field
Other Emerging Leaders on “Alzheimer&Apos”
- Lance Allen Johnson · University Of Kentucky$7,508,882
- Hyacinth Idu Hyacinth · University Of Cincinnati$6,781,590
- Yi Su · Weill Medical Coll Of Cornell Univ$6,486,733
- Julia Tcw · Icahn School Of Medicine At Mount Sinai$6,079,215
- Jessica Brooke Langbaum · Banner Health$6,050,741
- Timothy Yikai Huang · Sanford Burnham Prebys Medical Discovery Institute$5,936,362
Research focus
Alzheimer&AposCellsAnalogSmall MoleculeBiologicalCatalogsBiochemicalLeadProteinsIn VivoGeneticScreeningSignal TransductionInhibitorEnzymesBindingResponseStructureCollaborationsScaffoldTherapeutic DevelopmentActinsPenetranceDrug Kinetics
Grant awards (15)
Discovery and validation of CYP8B1 Inhibitors as probes for targeting Hepatocellular Carcinomas (HCC)$793,324
R01 · FY2025 · CA
Discovery of small molecules targeting Polycomb repressive complexes 1 and 2$469,742
R01 · FY2025 · CA
Discovery of apoE4 modulators for Alzheimerâs disease therapy$416,439
R01 · FY2025 · AG
Discovery of apoE4 modulators for Alzheimerâs disease therapy$439,375
R01 · FY2024 · AG
Development of allosteric HIPK4 inhibitors as non-hormonal male contraceptives$870,723
R33 · FY2023 · HD
HTS Targeting HIV-1 Protease Autoprocessing for First in Class Drug Discovery$510,656
R01 · FY2023 · AI
Discovery of apoE4 modulators for Alzheimerâs disease therapy$439,375
R01 · FY2023 · AG
Development of allosteric HIPK4 inhibitors as non-hormonal male contraceptives$870,606
R33 · FY2022 · HD
HTS Targeting HIV-1 Protease Autoprocessing for First in Class Drug Discovery$640,952
R01 · FY2022 · AI
Discovery of apoE4 modulators for Alzheimerâs disease therapy$467,938
R01 · FY2022 · AG
Development of allosteric HIPK4 inhibitors as non-hormonal male contraceptives$889,986
R33 · FY2021 · HD
HTS Targeting HIV-1 Protease Autoprocessing for First in Class Drug Discovery$636,059
R01 · FY2021 · AI
HTS Targeting HIV-1 Protease Autoprocessing for First in Class Drug Discovery$803,950
R01 · FY2020 · AI
Development of allosteric HIPK4 inhibitors as non-hormonal male contraceptives$417,573
R61 · FY2020 · HD
Development of allosteric HIPK4 inhibitors as non-hormonal male contraceptives$436,312
R61 · FY2019 · HD